Expected Results Report

CDC Model Performance Evaluation Program (MPEP) for

Mycobacterium tuberculosis Drug Susceptibility Testing

Attachment 11

Expected Results Report

March 2024 TB MPEP
Expected Results Report
Results listed are expected results and may not necessarily be consistent with aggregate data when results from all
participating laboratories are analyzed. Please refer to the forthcoming Final Report for aggregate data and detailed
information for each isolate.

Expected Growth-based Results
Isolate

RIF

INH

EMB

PZA

FQ

2024A

S

R (low-level*)

S

S

S

S

R (high-level†)

S

S

S

S

2024B

S

2024C
2024D

R

2024E

S
S

S
S

S

S

R

S

S

R

Second-line Drug
Resistances:

S

RBT

S

Note: RIF=rifampin, INH=isoniazid, EMB=ethambutol, PZA=pyrazinamide, FQ=fluoroquinolones,
RBT=rifabutin, S=susceptible, R=resistant. Growth-based DST results were obtained by agar proportion
method, except for pyrazinamide, in which MGIT™ was performed.
*Resistant at 0.2 µg/ml by agar proportion.
†Resistant at 0.2 and 1.0 µg/ml by agar proportion.

Expected Molecular Results

Isolate

rpoB*

2024A

inhA
C-15T

2024B
2024C
2024D
2024E

katG

Ser450Leu

Ser315Thr

gyrA

pncA

Ala90Val

His57Asp

Note: Empty cell=No mutation detected. Molecular results were obtained by whole genome sequencing.
High confidence mutations were not detected in these loci: fabG1, embB, ethA, eis, rrs, and tlyA.

* M. tuberculosis numbering system used [1, 2]

1. Andre, E., et al., Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clin
Microbiol Infect, 2017. 23(3): p. 167-172.
2. APHL, Issues in Mycobacterium tuberculosis complex (MTBC) Drug Susceptibility Testing: Rifampin (RIF), in APHL Issues in Brief: Infectious
Diseases. 2019, Association of Public Health Laboratories: Washington, D.C.